Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20361867 | 0.97 | GAA (0.44) | GAATSHRCTSKALDH1A1CYP2C19 | |
| SCHEMBL1107368 | 0.74 | GAA (0.44) | GAATSHRALDH1A1CYP2C19CHRM2 | |
| SCHEMBL9219357 | 0.74 | GAA (0.39) | GAATSHRALDH1A1CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL6253681 | 0.73 | — | — | |
| Isopropyl Alcohol SCHEMBL29056269 | 0.72 | GAA (0.42) | GAATSHRALDH1A1CYP2C19 | |
| SCHEMBL4913885 | 0.72 | CTSK (0.38) | CTSKALDH1A1 | |
| SCHEMBL11001316 | 0.72 | CTSK (0.34) | TSHRCTSKCHRM2CHRM4CHRM1 | |
| Ammonia Solution, Strong SCHEMBL5360181 | 0.72 | CTSK (0.32) | CTSK | |
| SCHEMBL7719672 | 0.72 | TSHR (0.45) | TSHRCTSKALDH1A1 | |
| SCHEMBL18196094 | 0.70 | GAA (0.37) | GAATSHRALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2448954-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | Rutgers, The State University of New Jersey (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011003025-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | TYMP, DTYMK, MTAP | GAA 1291/4885TSHR 1548/4885CTSK 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.